Evidence map›Paper›PMID 37091255›Full record

ArticleiScience2023

Structure-affinity and structure-residence time relationships of macrocyclic Gα

Jan H Voss, Max Crüsemann, Christian R O Bartling, Stefan Kehraus, Asuka Inoue, Gabriele M König, Kristian Strømgaard, Christa E Müller

Abstract read
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. How residence time works in allosteric drugs.Current opinion in structural biology · 2025
    Review
  4. Article
  5. Cyclic peptide inhibitors function as molecular glues to stabilize Gq/11 heterotrimers.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Rational Design of Ligands with Optimized Residence Time.ACS pharmacology & translational science · 2025
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jan H VossPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
Max CrüsemannInstitute of Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany.
Christian R O BartlingDepartment of Drug Design and Pharmacology, Center for Biopharmaceuticals, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Stefan KehrausInstitute of Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany.
Asuka InoueTohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Miyagi 980-8578, Japan.
Gabriele M KönigInstitute of Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany.
Kristian StrømgaardDepartment of Drug Design and Pharmacology, Center for Biopharmaceuticals, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Christa E MüllerPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The macrocyclic depsipeptides YM-254890 (YM) and FR900359 (FR) are potent inhibitors of Gα

Indexed as

BiochemistryBiological sciencesPharmacology

Identifiers

PMID37091255
PMCPMC10119753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.